

Follow us on :



Contents

- [News and Commentary](#)
- [Media Releases](#)
- [Latest Research](#)
- [The Industry](#)
- [Leading Companies in the Industry](#)

AUSTRALIA BIOTECHNOLOGY AND PHARMACEUTICALS

16 February 2021

Acquisdata Podcast – Gary J Phillips, CEO Pharmaxis Ltd. (ASX: PXS), 29/4/2020 – COVID 19 response

Gary Phillips, Pharmaxis CEO, discusses ensuring continuity of supply of its products throughout the crisis, the timeframe for trials of its unique anti-fibrotic treatment for a rare bone cancer, broader impacts for biopharma research and trials, the opportunity for the global industry and the potential for PXS respiratory products in the clinical aftermath of COVID -19.

<https://youtu.be/hgJkNOBbsqc>

This Week's News

- **SBS - People in Australia to start getting coronavirus vaccinations next week after arrival of first Pfizer doses - 15/2/2021**

The vaccine is awaiting final regulatory approval from the Therapeutic Goods Administration.

For the complete story, see: <https://www.sbs.com.au/news/people-in-australia-to-start-getting-coronavirus-vaccinations-next-week-after-arrival-of-first-pfizer-doses>

- **Mirage News - Illumina and University of Melbourne to set up A\$60m Genomics Hub - 15/2/2021**

Illumina is collaborating with the University of Melbourne and the Victorian Government to set up a A\$60 million Genomics Hub in Melbourne.

For the complete story, see: <https://www.miragenews.com/illumina-and-university-of-melbourne-to-set-up-514140/>

- **The Pharma Letter - Amendments to PBAC listing recommendations process - 15/2/2021**

Under the revised process, PBS-listing recommendations that have not been accepted by the applicant will be reviewed by the PBAC two years after the initial recommendation was made.

For the complete story, see: <https://www.thepharmaletter.com/article/amendments-to-pbac-listing-recommendations-process>

Other Stories

- Morningstar - Dechra Pharmaceuticals In Tri-Solfen Deal, Ups Medical Ethics Stake - 8/2/2021
- Stockhead - MGC Pharma is to become the first medicinal cannabis company to list on the London Stock Exchange - 4/2/2021
- Nasdaq - Australia to buy 10 mln additional doses of Pfizer COVID-19 vaccine - 3/2/2021
- UNSW Newsroom - Revolutionary eye drop trial starts for common eye diseases - 3/2/2021
- Xinhua - Australian PM reveals plan to vaccinate entire country by October - 1/2/2021

Media Releases

- Neuren Pharmaceuticals Limited (ASX: NEU) - Neuren adds Prader-Willi syndrome to pipeline with compelling results for NNZ-2591 in pre-clinical model - 16/2/2021
- CSL Limited (ASX: CSL) - Local Manufacturing of COVID-19 Vaccine Reaches Final Stages - 12/2/2021
- Starpharma Holdings Limited (ASX: SPL, OTCQX: SPHRY) - Starpharma signs DEP® ADC Research Agreement with MSD - 12/2/2021
- Mesoblast Limited (ASX: MSB; NASDAQ: MESO) - Mesoblast Phase 3 Chronic Low Back Pain Results - 11/2/2021
- Alterity Therapeutics Limited (ASX: ATH, NASDAQ: ATHE) - Alterity announces funding from Michael J. Fox Foundation for ATH434 dose optimization for Parkinson's disease clinical trials - 9/2/2021

NO.: 25040



AUSTRALIA BIOTECHNOLOGY AND PHARMACEUTICALS

Latest Research

- High-Throughput Screening and Characterization of Phenolic Compounds in Stone Fruits Waste by LC-ESI-QTOF-MS/MS and Their Potential Antioxidant Activities - By Yili Hong, Zening Wang, Colin J. Barrow, Frank R. Dunshea, Hafiz A. R. Suleria

Overviews of Leading Companies

AcruX Limited (ASX: ACR)
 Alterity Therapeutics Limited (ASX: ATH, NASDAQ: ATHE)
 Benitec Biopharma Limited (ASX: BLT)
 Bionomics Limited (ASX: BNO, OTCQX: BNOEF)
 Clinuvel Pharmaceuticals Limited (ASX: CUV)
 CSL Limited (ASX: CSL)
 Genera Biosystems Limited
 IDT Australia Limited (ASX: IDT)
 Immutep Limited (ASX: IMM, NASDAQ: IMMP)
 Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA)
 Mayne Pharma Group Limited (ASX: MYX)
 Medical Developments International Limited (ASX: MVP)
 Medlab Clinical Limited (ASX: MDC)
 Mesoblast Limited (ASX: MSB; NASDAQ: MESO)
 MMJ Group Holdings Limited (ASX: MMJ)
 Monash IVF Group (ASX: MVF)
 Neuren Pharmaceuticals Limited (ASX: NEU)
 Palla Pharma Limited (ASX: PAL)
 Pharmaxis Limited (ASX: PXS)
 PolyNovo Limited (ASX: PNV)
 Sirtex Medical Limited
 Starpharma Holdings Limited (ASX: SPL, OTCQX: SPHRY)
 Viralytics Limited (NYSE: MRK)
 Vita Life Sciences Limited (ASX: VLS)

Senior Associate: Joseph Hang Ellision

Are you MIFID II ready? You might like to talk to Acquisdata about our Bespoke Research offering. www.acquisdata.com/bespoke-research

Looking for
more in-depth
research ?



We also produce in-depth reports on a range of newly emerging market sectors. See our sister company's website at www.macrosourcemedia.com

Topics include: Deep Sea Mining, Fintech, Robotics, Smart City Technologies, High-Tech Shipping, UAV (drones), Internet of Things, Cybersecurity, Artificial Intelligence Software and more.

NO.: 25040



AUSTRALIA BIOTECHNOLOGY AND PHARMACEUTICALS

Acquisdata InView

Latest Version

Acquisdata InView - BioPharma - June 2019

<https://www.docdroid.net/5PeNs6Y/acquisdata-inview-biopharma-dr-peter-french-june-2019.pdf>

Dr Peter French, Biotechnology Consultant, speaks with Acquisdata's Fiona Fox about superbugs, bacteriophage and CRISPR gene-editing technology and biopharma companies working in this space.

View the playlist on Acquisdata's YouTube channel here:

<https://www.youtube.com/playlist?list=PLLht7jPps2v2runHsQivr-ANhIKQ9Zy-v>

Earlier Biopharma InViews:

Acquisdata InView - Biopharma - August 2018 (Topic: cancer diagnostics)

http://www.reportaldata.com/video/InView_BioPharma_201809/Acquisdata%20InView%20-%20BioPharma%20-%20Dr%20Peter%20French%20August%202018.pdf

View the playlist here: <https://www.youtube.com/playlist?list=PLLht7jPps2v1i9AyH4yJbFsATaAq8eYNx>

ABOUT InView

Learn from industry experts with Acquisdata InView. The latest addition to the Acquisdata suite of information products, Acquisdata InView features interviews with experts across a range of industries on topical issues.

Acquisdata is excited to connect with experts from across the world for InView. InView also opens the way for more in-depth Executive SnapShot interviews with company executives for their perspective on what's happening in their company and industry.

Coming up next will be Defence Expert, Rowan Moffitt, to give his view on developments in the defence and armaments industry for Acquisdata InView - Defence.

Acquisdata InView is available via the Acquisdata website, Reuters Eikon and Acquisdata's extensive network of distributors.

Industry SnapShots

Published by **Acquisdata Pty Ltd**

A.C.N. 147 825 536

ISSN 2203-2738 (Electronic)

©Acquisdata Pty Ltd 2021

www.acquisdata.com

Disclaimer of Warranties and Liability

Due to the number of sources from which the information and services on the Acquisdata Pty Ltd Service are obtained, and the inherent hazards of electronic distribution, there may be delays, omissions or inaccuracies in such information and services. Acquisdata Pty Ltd and its affiliates, agents, sales representatives, distributors, and licensors cannot and do not warrant the accuracy, completeness, currentness, merchant ability or fitness for a particular purpose of the information or services available through the Acquisdata Pty Ltd service. In no event will Acquisdata Pty Ltd, its affiliates, agents, sales representatives, distributors or licensors be liable to licensee or anyone else for any loss or injury caused in whole or part by contingencies beyond its control in procuring, compiling, interpreting, editing, writing, reporting or delivering any information or services through the Acquisdata Pty Ltd Service. In no event will Acquisdata Pty Ltd or its affiliates, agents, sales representatives, distributors or licensors be liable to licensee or anyone else for any decision made or action taken by licensee in reliance upon such information or services or for any consequential, special or similar damages, even if advised of the possibility of such damages. licensee agrees that the liability of Acquisdata Pty Ltd, its affiliates, agents, sales representatives, distributors and licensors, if any, arising out of any kind of legal claim (whether in contract, tort or otherwise) in any way connected with the Acquisdata Pty Ltd service shall not exceed the amount licensee paid for the use of the Acquisdata Pty Ltd service in the twelve (12) months immediately preceding the event giving rise to such claim.